報價延遲最少15分鐘:2024/12/24 13:21 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.42 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.96/-0.50
|
|
企業價值
4.46M
|
| 資產負債 |
|
每股賬面淨值
-0.16
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
18.63K
|
|
每股收益
0.06
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/24 13:21 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others. |